Oragenics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Oragenics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 4.5 times its market value (net cash). Higher than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 6,229% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-40.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 69% of Healthcare companies in United States.
Cash Cushion Ratio
4.5× cashCash, after subtracting all debt, is 4.5 times its market value (net cash).
Higher than almost all Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Oragenics, Inc. made a loss over the last year. Oragenics, Inc. owes $0.17 for every $1 it owns. Oragenics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOragenics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.30The share price is 0.30 times Oragenics, Inc.'s book value per share, lower than 96% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Oragenics, Inc.'s shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$6 MWhat Oragenics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$1.37Net worth divided by the number of shares. The share price of $0.41 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-1307.1%Oragenics, Inc. lost 1307.1% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
Owes vs Owns
0.17×Oragenics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
NoneOragenics, Inc. does not currently pay a dividend.
Profit growth
LossOragenics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredOragenics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOragenics, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Oragenics, Inc.: $2 M ÷ $6 M (31 Mar 2026) = 0.3.
What is Oragenics, Inc.'s return on equity?
Oragenics, Inc. lost 1307.1% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
How much does Oragenics, Inc. owe compared with what it owns?
Oragenics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does Oragenics, Inc. pay a dividend?
No. Oragenics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.